key: cord-0710328-8vjlrs1l authors: Bylicki, Olivier; Delarbre, David; Mayet, Aurélie; Ferrier, Audrey; Perisse, Anne; Malle, Carine; Cobola, Jacques; Bronstein, Antoine; Menoud, Nastasia; Valero-Biance, Elodie; Ferraris, Olivier; Janvier, Frédéric; Tournier, Jean-Nicolas title: Neutralizing antibodies response to SARS-CoV-2 are persistent 9 months post symptom onset in mild or asymptomatic patients date: 2021-09-08 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.09.002 sha: dede51222edbf9967f97176f1633e66ec0255652 doc_id: 710328 cord_uid: 8vjlrs1l Objective A better understanding of immune response against SARS-CoV-2 infection is critical to predict its dynamics within general population and its impact on vaccination strategy. We assessed both neutralizing antibody (Nab) activity persistence and SARS-CoV-2 serology in serum samples of mild and asymptomatic patients nine months post symptom onset (PSO) in a primary care context among immunocompetent adults. Methods A longitudinal cohort of crewmembers (CM) exposed to COVID-19 during the SARS-CoV-2 outbreak on the French aircraft carrier in April 2020 was created. CM infected with COVID-19 and having a positive serology at the end of quarantine were tested at 9-months PSO. Samples were collected at 18 and 280-days PSO. For each patient, both serology and serum viral neutralizing activity were performed. Results We analyzed 86 CM. Samples were collected at 18 and 280-days PSO. The seroconversion rate was 100% and 93% (82/86) at 18 and 280 days, respectively, while 72.7% of patients exhibited Persistent Nab at 9 months, regardless of disease severity. Conclusion Nab persists up to 9 months following asymptomatic/mild COVID-19 among young adults regardless of serology results at that time. A better understanding of immune response against SARS-CoV-2 infection is critical to predict its dynamics within general population and its impact on vaccination strategy. We assessed both neutralizing antibody (Nab) activity persistence and SARS-CoV-2 serology in serum samples of mild and asymptomatic patients nine months post symptom onset (PSO) in a primary care context among immunocompetent adults. A longitudinal cohort of crewmembers (CM) exposed to COVID-19 during the SARS-CoV-2 outbreak on the French aircraft carrier in April 2020 was created. CM infected with COVID-19 and having a positive serology at the end of quarantine were tested at 9-months PSO. Samples were collected at 18 and 280-days PSO. For each patient, both serology and serum viral neutralizing activity were performed. We analyzed 86 CM. Samples were collected at 18 and 280-days PSO. The seroconversion rate was 100% and 93% (82/86) at 18 and 280 days, respectively, while 72.7% of patients exhibited Persistent Nab at 9 months, regardless of disease severity. Nab persists up to 9 months following asymptomatic/mild COVID-19 among young adults regardless of serology results at that time. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 19 , emerged in late 2019 and rapidly spread worldwide, causing a global pandemic (Lipsitch, Swerdlow, et Finelli 2020) . Despite many insights on the virus, data relative to long-term immune response is quite scarce (Huang et al. 2020) , although this question is clinically highly relevant. SARS-CoV-2infection elicits humoral response with specific antibodies against the viral surface spike (S). These antibodies are detectable 2 weeks after disease onset and persist beyond six months post symptom onset (PSO) (Gaebler et al. 2021) . Neutralizing antibodies (Nab) are supposed to play a crucial role in immune response and their steadiness over time is discussed. Nab level have been correlated with both anti-SARS-CoV-2 IgG titers and clinical status. Antibodies dynamics over time is less well described among mild and asymptomatic patients for whom interpretation of humoral response is hazardous since time from seroconversion might be impossible do define. It is also less clear whether serology results are predictive or not for Nab remaining potential with a strong correlation in this group. Herein, we overcome these issues by assessing both Nab activity persistence in serum samples in mild and asymptomatic patients nine months PSO in a cohort of French Navy sailors after a large outbreak onboard the nuclear aircraft carrier Charles de Gaulle. A COVID-19 outbreak occurred in April 2020 on the French Navy nuclear aircraft carrier Charles de Gaulle. Among crewmembers (CM), 64% (1,121/1,769) tested positive for SARS-CoV-2 by reverse-transcriptase-polymerase chain reaction (RT-PCR). Genomic analysis has identified SARS-CoV-2 viruses from clade 20C. SARS-CoV-2 serologic testing performed in 1,706 CM showed that 60% were anti-body-positive at the end of the quarantine. Among 682 CM that agreed to participate in the longitudinal follow-up cohort study COV-PA (IDRCB 2020-A02397-32), 86 CM selected were tested again in January 2021 (9-month PSO). Progression/Improvement Scale". All data were collected in the context of care from completely anonymized files, in accordance with French and European laws, including the General Data Protection Regulation. All patients were informed and provided written consent to use their data. COV-PA study was approved by the regional research ethics committee on December 7, 2020. The Elecsys anti-SARS-CoV-2 assay (Roche®) is an electrochemiluminescence immunoassay (ECLIA) for the detection of Total Immunoglobulins (TI) (IgM, IgG, IgA) to SARS-CoV-2 on Cobas automatized system (Roche®). This sandwich immunoassay is designed to preferentially detect, mature, high-affinity antibodies to the highly immunogenic SARS-CoV-2 nucleocapsid (N) protein. Test was non-reactive when sample index/cut off index (COI) was < 1.0 and positive when it was ≥ 1.0. Specificity and sensitivity were described as excellent and showed good correlation with viral neutralizing activity ). Vero cells (ATCC CCL-81) were grown in DMEM medium (Gibco, cat. no. 31966021, ThermoFisher Scientific) . At confluence, the Vero cells were harvested and subsequently seeded at 1.5.105/mL in 96-well plates in order to reach confluence after 72 h at 37 °C under a 5% CO2 atmosphere. Serial dilutions of stock viruses were made to the infection medium [DMEM (Gibco, cat. no. 31966021, ThermoFisher Scientific) supplemented with 50 U/mL penicillin, 50 mg/mL streptomycin (Gibco cat. no. 15070063, ThermoFisher Scientific), containing TPCK-trypsin (Sigma, cat. no. T1426), at a final concentration of 1 µg/mL. For the Neutralization test, SARS-CoV-2 virus (BetaCoV/France/IDF0372/2020 strain) from clade 19A was isolated by the National Reference Center (CNR) for Respiratory Viruses (Institut Pasteur) as previously described (Lescure et al. 2020 ). The strain BetaCoV/France/IDF0372/2020 was supplied by the CNR for Respiratory Viruses hosted by Institut Pasteur (Paris, France) and headed by Pr. Sylvie van der Werf. The human sample from which strain BetaCoV/France/IDF0372/2020 was isolated has been provided by Dr. X. Lescure and Pr. Y. Yazdanpanah from the Bichat Hospital, Paris, France. Moreover, the strain BetaCoV/France/IDF0372/2020 was supplied through the European Virus Archive goes Global (Evag) platform, a project that has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 653316. Briefly, 50 µl of tenfold serial dilutions of SARS-CoV-2 virus were inoculated into eight replicate wells. The 96-well microplates were then incubated at 37°C under a 5% CO2 atmosphere, and the cytopathic effect (CPE) was checked 5 days after inoculation. The virus titre was calculated according to the method of Reed & Muench (REED et MUENCH 1938) . Nab tests were performed in flat-bottomed microtiter plates (96 wells), 3 days after seeding of the Vero cells. Twofold serial dilutions of inactivated sera starting at a 1/40 dilution were mixed with an equal volume of SARS-CoV-2 virus (100 TCID50/50 µL), and incubated for 1 h at 37°C. One hundred microliters of the serum-virus mixture and 100 µl of infection medium were inoculated in each well (4 wells/dilution), and the plates were incubated for 5 days at 37°C in 5% CO2 atmosphere. The cytopathic effect (CPE) was checked 5 days after inoculation. Neutralization titers were expressed as the inverse of the final dilution of serum that neutralized 50% of the inoculated wells. Since we observed no CPEs due to serum cytotoxicity at a dilution of 1/60, a Neutralization titer of 60 was considered as positive. Continuous variables are expressed as the mean and interquartile range (IQR) and discrete variable are expressed as numbers and percentages. Two-sided Wilcoxon signed-rank test was used to compare serum TI and Nab titers for CM between M0-M9 and TI versus Nab titers at 9-month PSO, respectively. All analyses were computed with R software, version 4.3.0. A 5% significance level was retained for all the analyses. The demographic and clinical characteristics of the 86 participants analyzed and their Covid-19 status are reported in Table 1 . All participants presented with COVID-19 infection during the outbreak, including 17.4 % being asymptomatic. Three CM (3.4 %) were hospitalized for oxygen administration. All CM had detectable positive SARS-CoV-2 serology at the end of quarantine. First and second samples were collected at 18 and 280 days after PSO, respectively. The average rate for COI was 18.0 IQR: 3.1-25.8 in the first sample. At 9-month PSO, the seropositive rate was 93.0 % (80/86) and mean COI level was 31.0 IQR 4.8-32.7. For the 3 CM who required hospitalization, we observed a 100% seropositive rate for 9month PSO with a 124.2 average COI vs. 27.8 for the non-hospitalized CM. No significant difference was observed in the positivity kinetics of the serology depending on the COVID-19 infection severity. Six CM had COI < 1.0 at 9-month PSO. Five presented with symptomatic COVID-19 and one patient with asymptomatic form. We noted that these seronegative patients at 9-month PSO had initial lower COI levels: mean of 7.0 vs 18.8 (p <0.01). The median Nab titer 9-month PSO was 1:96 IQR 1:57-1:113. With a 1:60 threshold, 72.1 % (62/84) were considered positive. Table 2 details the characteristics of CM depending on the presence of Nabs: there was no statistical difference in terms of type of infection, symptoms or anti-IgG-SARS-CoV-2 rate. Among the six patients no longer showing anti-IgG-SARS-CoV-2, five had a neutralizing antibody titer greater than 1:60. Studies focusing on Nab detectability over time mainly report data from the first year of the COVID-19 outbreak, thus mainly following exposure to the SARS-CoV-2 initial strain. Nab last up to 12 months PSO with discrepancies between studies with regards to waning (Betton Passive transfer of Nab is protective against severe SARS-CoV-2 infection or reinfection in multiple animal models (Kim et al. 2021; McMahan et al. 2021; Rogers et al. 2020) . A fatal outcome was correlated with Nab deficiency in a cohort of 162 patients (Dispinseri et al. 2021 ). Moriyama et al. mentioned a limited efficacy of Nab toward B.1.351 (501&Y.V2) and P.1 (501Y.V3) variants using 188 sera obtained from symptomatic patients between June 2020 and February 2021 (Moriyama et al. 2021 ). On the other hand, the administration of convalescent plasma to patients with COVID-19 improves both morbidity and mortality, particularly when used in the early stages of the disease and even for critical cases (Hegerova et al. 2020; Kim et al. 2021 ). More recently, treatment with neutralizing monoclonal antibody bamlanivimab in association with etesevimab has been proven to reduce viral load, hospitalization and mortality incidence (Dougan et al. 2021; Gottlieb et al. 2021) . mRNA based vaccines have been proven to elicit a high Nab rate (Chu et al. 2021; Pratesi et al. 2021) . A randomized controlled trial also reported the efficacy of the mRNA-1273 SARS-CoV-2 vaccine to prevent Covid-19 illness, but with a median follow-up duration of 2 months (Baden et al. 2021) . Whereas SARS-CoV-2 B.1.1.7 (alpha) and B.1.526 (iota) variants remain susceptible to vaccine-or infection-elicited neutralizing activity, more recently emerged B.1.617.1 (kappa) and B.1.617.2 (delta) variants are less susceptible to Nab(V. V. V.-V. Edara et al. 2021; Liu et al. 2020) . Thus, how the persistence of neutralization response following vaccine, or SARS-CoV-2 infection confers protection against new variants is still to be demonstrated. The present study included individuals infected during the same epidemic event and followed them prospectively, allowing a reliable chronology analysis. While binding antibodies stability is known to be linked to disease severity, this cluster still exhibited a high and persistent seroconversion level. We also observed an increased titer range at 9 months vs. 1 month, but the timing at first sample collection might have been too early to capture the initial IgG peak as a whole. Although not likely to be correlated with protective efficacy, the low seroreversion rate (7% -6/86) of CM at 9-month PSO strongly suggests the persistence of a significant humoral response against SARS-COV-2 within a young population. The mean COI was higher for three hospitalized CM, but serological response level was irrespective of both symptoms 'intensity and duration among others. Usually assessed during shorter follow-up period, Nab persisted at a detectable level even 9months PSO for the majority of patients in the present study (Chen et al. 2020; Crawford et al. 2020; Gaebler et al. 2021; Iyer et al. 2020; Legros et al. 2021; Reynolds et al. 2020; Wajnberg et al. 2020 ). Likewise, we observed a persistent serum neutralizing activity for asymptomatic patients whose contamination period was clearly determined (Reynolds et al. 2020; Brochot et al. 2020; Jonsdottir et al. 2021) . Former studies including severe forms of SARS-CoV-2 infection identified a significant Nab difference according to disease severity (Chen et al. 2020; Iyer et al. 2020; Wajnberg et al. 2020; . However, this correlation might be unstable over time (Crawford et al. 2020) . Like other publications enrolling mild and/or asymptomatic patients, no Nab titer difference was observed between those groups in this work (Jonsdottir et al. 2021; Reynolds et al. 2020) . IgG stability and neutralizing activity both rely on targeted antigen (Wajnberg et al. 2020; . This correlation is inconstantly observed and appears to be mostly influenced by time of Nab assessment PSO as well as patients ' profile (2021; Iyer et al. 2020; Wang et al. 2020) . Five patients showed persistent Nab and negative serology. Nevertheless, since a nucleocapsid-based serology was used in this work, its correlation with Nab titers targeting the spike protein was judged irrelevant and not assessed. Due to homogeneous patients' profile, the present study may not reflect general population characteristics, but provides crucial information on a group not usually targeted in the highest priority by vaccination programs, highlighting the persistence of Nab at 9 months-PSO as well as an upward trend in nucleocapsid-based serology titer. We did not observed any reinfection at the time of the present publication, cutting down some doubts towards protective immunity, for non-severe cases. Nab persists up to 9 months PSO following asymptomatic/mild COVID-19 among young adults regardless of serology results at that time. The Authors would like to thank all the crewmembers who participated in the study and the entire staffs of HIA Saint Anne Clinical Unit Research who actively contributed to the data collection. None of the authors have any conflict of interest to declare. The COV-PA cohort is supported by the Military National Social Security "Caisse Nationale Militaire Securité Sociale" (CNMSS). COV-PA study was approved by the regional research ethics committee on December 7, 2020. (IDRCB 2020-A02397-32) « Efficacy and Safety of the MRNA-1273 SARS-CoV-2 Vaccine « Sera Neutralizing Activities against SARS-CoV-2 and Multiple Variants Six Month after Hospitalization for COVID-19 ». Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America Anti-Spike, Anti-Nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals « SARS-CoV-2 Neutralizing Antibody Levels Are Correlated with Severity of COVID-19 Pneumonia « Persistence of Neutralizing Antibody Response up to One Year after Asymptomatic or Symptomatic SARS-CoV-2 Infection « A Preliminary Report of a Randomized Controlled Phase 2 Trial of the Safety and Immunogenicity of MRNA-1273 SARS-CoV-2 Vaccine Dynamics of Neutralizing Antibody Titers in the Months after SARS-CoV-2 Infection « Weak Correlation between Antibody Titers and Neutralizing Activity in Sera from SARS-CoV-2 Infected Subjects » « Naturally Acquired SARS-CoV-2 Immunity Persists for up to 11 Months Following Infection « Neutralizing Antibody Responses to SARS-CoV-2 in Symptomatic COVID-19 Is Persistent and Critical for Survival » « Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 « Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination « Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants « Evolution of Antibody Immunity to SARS-CoV-2 » « Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial « Use of Convalescent Plasma in Hospitalized Patients with COVID-19: Case Series « A Systematic Review of Antibody Mediated Immunity to Coronaviruses: Kinetics, Correlates of Protection, and Association with Severity » « Persistence and Decay of Human Antibody Responses to the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 Patients » « Titers of Neutralizing Antibodies against SARS-CoV-2 Are Independent of Symptoms of Non-Severe COVID-19 in Young Adults « Critical Role of Neutralizing Antibody for SARS-CoV-2 Reinfection and Transmission « A Longitudinal Study of SARS-CoV-2-Infected Patients Reveals a High Correlation between Neutralizing Antibodies « Clinical and Virological Data of the First Cases of COVID-19 in Europe: A Case Series et Lyn Finelli. 2020. « Defining the Epidemiology of Covid-19 -Studies Needed « Potent Neutralizing Antibodies against Multiple Epitopes on SARS-CoV-2 Spike » « Correlates of Protection against SARS-CoV-2 in Rhesus Macaques » « Temporal Maturation of Neutralizing Antibodies in COVID-19 Convalescent Individuals Improves Potency and Breadth to Circulating SARS-CoV-2 Variants « BNT162b2 MRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers « A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12 « Discordant Neutralizing Antibody and T Cell Responses in Asymptomatic and Mild SARS-CoV-2 Infection » « Isolation of Potent SARS-CoV-2 Neutralizing Antibodies and Protection from Disease in a Small Animal Model « SARS-CoV-2 Antibody Kinetics Eight Months from COVID-19 Onset: Persistence of Spike Antibodies but Loss of Neutralizing Antibodies in 24% of Convalescent Plasma Donors « Temporal Profiles of Viral Load in Posterior Oropharyngeal Saliva Samples and Serum Antibody Responses during Infection by SARS-CoV-2: An Observational Cohort Study « Robust Neutralizing Antibodies to SARS-CoV-2 Infection Persist for Months « Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients ». Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America « Persistence of Antibody and Cellular Immune Responses in COVID-19 Patients over Nine Months after Infection « Potently Neutralizing and Protective Human Antibodies against SARS-CoV-2 »